22 "Melanoma" clinical trials found.
Prospective Randomized Blinded Placebo-Controlled Phase 2b Trial Of An Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells(DC) Vaccine Vs Unloaded YCWP + DC In Stage 3 And Stage IV (Resected) Melanoma To Prevent Recurrence
If you have been diagnosed with melanoma and have received treatment for stage III or stage IV melanoma that has been surgically resected (removed) ...
A Phase 1/2 Study of the Safety Tolerability and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) A Study of the Safety Tolerability and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
The goal of this Phase 1/2 study is to determine in the first part (Phase 1) dose-escalation assessment of the safety and tolerability of ...
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Using Cancer Registry Data to Promote Proactive Tobacco Cessation Among Adult Cancer Survivors U48
This is a population-based randomized controlled trial of 600 patients with a diagnosis of cancer in the past 2 years and registry indicating smoking ...
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer Non-small Cell Lung Cancer or Melanoma A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer Non-small Cell Lung Cancer or Melanoma That Has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone ...
A Platform Study Exploring the Safety Tolerability Effect on the Tumor Microenvironment and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
This is an open-label, Phase 1b, 2 Part (Part 1a and Part 1b), multi-center study. Part 1a utilizes a 3+3 design to evaluate pembrolizumab ...
Multi-Center Phase 2 Open-Label Study To Evaluate Safety And Efficacy In Subjects With Melanoma Metastatic To The Brain Treated With Nivolumab In Combination With Ipilimumab Followed By Nivolumab Monotherapy
If you have been diagnosed with metastatic melanoma that has spread to your brain, you may qualify to participate in a study investigating how ...
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and ...
A Phase 1b/2 Open-label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell ...
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab ...